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Solid dispersion technology for poorly soluble drugs 191. Introduction
It is estimated that most compounds undergoing development at
the present time are subjected to dissolution problems1. To meet
this pharmaceutical challenge, various solubilization technologies
have been developed including solid dispersions, nanocrystals,
cyclodextrin complexes and lipid formulations. With accelerated
increase in the number of FDA-approved products in recent years
(Table 1), solid dispersion is now ﬁrmly established as a platform
technology for the formulation of poorly-soluble drugs. Speciﬁ-
cally, solid dispersion technology has been successfully applied to
develop formulations with a high drug loading (e.g. 375 mg per
tablet in Incivek) and/or containing drugs with a high tendency to
crystallize (as indicated by the high melting point of 291 1C of
ivacaftor in Kalydeco) (Table 1).
At least three methods of preparing solid dispersions have been
successfully used in commercial production2 (Table 1). These are
melt extrusion, applicable to drugs with not-very-high melting
points3, spray drying, useful for drugs soluble in at least one
volatile solvent4, and co-precipitation, useful for drugs with high
melting point and low solubility in common organic solvents5. The
encouraging progresses should more-or-less ease previous con-
cerns on solid dispersion regarding its drug loading, manufactur-
ing, and stability issues6.
Historically, the term “solid dispersion” was deﬁned as a
dispersion of drug in a solid matrix where the matrix was either
a small molecule or polymer. The dispersed state has included
many forms such as eutectic mixtures, crystalline/glass solutions,
and amorphous/crystalline suspensions7,8. Taking account of its
currently most-used form (Table 1), a solid dispersion can now be
more narrowly deﬁned as dispersion of drug in an amorphous
polymer matrix where the drug is preferably in the molecularly
dispersed state (i.e. as a glass solution to use the old term,
Fig. 1A). The following discussion is limited to systems that ﬁt
this more limited deﬁnition.
Although other additives (particularly surfactants) are often
included and products may be made using polymer mixtures, solid
dispersions are mainly drug–polymer two-component systems.
As discussed below, the drug–polymer interaction is fundamental
to understanding the most important issues that arise in the designTable 1 Examples of FDA-approved medicines that use solid dispe
Product name API Polymera Maximum API dose
per tablet or capsule
Cesamet Nabilone PVP 1
Sporanox Itraconazole HPMC 100
Prograf Tacrolimos HPMC 5
Kaletra Lopinavir/ritonavir PVP/VA 200/50
Intelence Etravirine HPMC 200
Zotress Everolimus HPMC 0.75
Novir Ritonavir PVP/VA 100
Onmel Itraconazole HPMC 200
Incivek Telaprevir HPMCAS 375
Zelboraf Vemurafenib HPMCAS 240
Kalydeco Ivacaftor HPMCAS 150
aBest guess based on the inactive ingredient list, patents and other literat
bInformation based on the drug product labels from the FDA website.
cFrom Merck index or otherwise speciﬁed.
dDecomposition temperature.
eFrom Brough and Williams2.of a solid dispersion viz. the drug loading, stability of the system
and its dissolution performance. The objective of this short review
is to summarize our current understanding of solid dispersions in
terms of this important factor. Other aspects related to solid
dispersions can be found in a number of excellent reviews already
in the literature6,9–13.2. Drug–polymer interactions in the solid state
2.1. Phase diagram and phase separation
A solid dispersion is a deceptively simple two component system
where the drug and the polymer act as solute and solvent,
respectively. Despite this apparent simplicity, these two-component
systems can form multiple structures depending on their composition
and sample processing history14 (Fig. 1). When the drug loading is
lower than the equilibrium solubility of drug in polymer, the drug is
molecularly dispersed within the polymer matrix (Fig. 1A) and
should form a thermodynamically stable, homogeneous solution. This
is the most desirable structure of solid dispersion. However, for most
drug–polymer pairs, this situation only appertains at very low drug
loading and/or high temperature (see below). As temperature is
decreased, the mixture becomes a supersaturated solution and the
drug tends to precipitate out. This can result in a dispersion of
crystalline drug particles in a polymer matrix, in which the drug
concentration corresponds to its equilibrium solubility at that
temperature (Fig. 1B). Alternatively, as drug crystallization is a slow
process with a higher energy barrier compared to amorphous phase
separation, an intermediate meta-stable structure may form in which
amorphous drug aggregates are dispersed in a polymer matrix
containing drug at its amorphous solubility at that temperature
(Fig. 1C).
As with all multi-component systems, a phase diagram is very
useful to understand its structure under different conditions and to
design a processing protocol to obtain a desired structure. By
analogy with many small molecule–polymer systems described in
the literature15,16, a simpliﬁed drug–polymer phase diagram is
shown in Fig. 2A. The curve of drug solubility in the polymer
(solid curve) is particularly important not only to select the lowerrsion technologies.
(mg)b
API Tm (1C)
c Solid dispersion
preparation methode
Year of
approvalb
160 — 1985
166 Spray drying on sugar beads 1992
128 Spray drying 1994
125/122 Melt extrusion 2005
265d Spray drying 2008
115 Spray drying 2010
122 Melt extrusion 2010
166 Melt extrusion 2010
246 Spray drying 2011
272 Co-precipitation 2011
291 Spray drying 2012
ure information.
Figure 1 The three possible structures of a drug/polymer solid dispersion where hexagonal symbols represent drug molecules and curvy lines
represent polymer chains. (A) The ideal structure of a solid dispersion where the drug is molecularly dispersed in the polymer matrix; (B) a drug–
polymer system in which crystalline drug formation has occurred and (C) a drug–polymer system containing amorphous drug-rich domains
dispersed in the polymer matrix.
Y. Huang, W.-G. Dai20limit of the processing temperature to obtain a molecular disper-
sion by melt extrusion, but also to understand the supersaturation
level of such dispersions when they are cooled down (e.g., to the
storage temperature). The glass transition temperature Tg curve
(dotted curve) is also important since the glass transition may
freeze the system in a particular structure, a knowledge of which is
essential to predicting the storage stability of a solid dispersion.
Usually, the Tg curve obeys the Gordon–Taylor equation and Tg
decreases continuously from that of the pure polymer to that of
pure drug (Fig. 2A). However, the amorphous phase separation
may complicate the Tg proﬁle, as discussed below.
Ideally, a molecular dispersion should be kinetically-stable at its
storage temperature as this is important for its dissolution proﬁle
(discussed in Section 3). Such stability can be achieved by carefully
selecting polymer excipients, the polymer/drug ratio and the
processing parameters. Indeed, many solid dispersions show no
drug crystallization during characterization by thermal analysis and
X-ray diffraction. However, it should be noted that such character-
ization methods are rather insensitive to crystal formation and can
only detect 1–5% crystals in a given sample9,17–19.
Alternative to drug crystallization, amorphous phase separation
may also take place (Fig. 2B). This can occur very rapidly,
especially when the drug/polymer composition falls into the
spinodal zone9,14,16 (not shown in Fig. 2B for simplicity) where
there is no free energy barrier to separation. At least two situations
can occur as shown in Fig. 2A and B. In Fig. 2A, the phase
diagram applies to a system where the amorphous phase separation
curve does not intersect with the glass transition temperature
curve. In this case, amorphous phase separation can occur attemperatures below the whole glass transition temperature curve as
in the case of the fenbufen/PVP system. In Fig. 2B, the phase
diagram is for a system where the two curves intersect at
pharmaceutically relevant temperatures as for example in the
felodipine/poly(acrylic acid) system. In the ﬁeld of polymer
science, the intersection point of the two curves is known as the
Berghmans' Point16,20. As temperature falls and amorphous phase
separation proceeds, the compositions of the drug-rich and
polymer-rich phases follow the phase line (shown as the dashed
curve in Fig. 2B). When the temperature reaches that of the
Berghmans' Point, the polymer-rich phase reaches its glass
transition temperature, below which further phase separation does
not occur. Consequently, the ﬁnal solid dispersion is amorphous
phase separated with the composition of the polymer matrix at
Berghmans' Point, while the amorphous drug phase is almost pure
drug, because the polymer–small molecule amorphous separation
curve is usually highly asymmetric15 as shown in Fig. 2B.
It should be emphasized that the phase diagrams shown in
Fig. 2 do not represent the only possibilities because both assume
that the drug and polymer are completely miscible above
the drug melting point which may not always be the case.
In addition, depending on the relationship between the drug–
polymer interaction parameter and temperature (Eq. (4), see
Section 2.3), amorphous phase separation can take place both
when temperature decreases (below the upper critical solution
temperature, or UCST, Fig. 2B) and when it increases (above the
lower critical solution temperature, or LCST) (not shown).
Thermal analysis using differential scanning calorimetry (DSC)
is often used to characterize solid dispersions but phase separation
Solid dispersion technology for poorly soluble drugs 21in a solid dispersion is difﬁcult to detect when the phase domains
are small. Thus, when a drug melting event is absent and only one
glass transition temperature Tg is observed, the solid dispersion is
usually assumed to be a homogeneous solution when, in fact, itFigure 2 Possible temperature–composition phase diagrams for a
drug–polymer solid dispersion showing (A) the situation where an
amorphous phase separation curve does not interact with the glass
transition temperature curve and (B) the situation where the amor-
phous phase separation curve interacts with the glass transition
temperature curve.
Figure 3 Schematic illustration of a solid dispersion inmay contain segregated amorphous domains that are too small to
be detected. For example, Qian et al.21 demonstrated that a solid
dispersion showing one Tg in thermal analysis has phase separated
domains approximately 100 μm in size using confocal Raman
microscopy. This is an interesting observation that needs to be
conﬁrmed in further studies. Another value in the literature22 on
the Tg detection size limit of amorphous phase domains is 30 nm,
which was based on a single and inconclusive study of a block
copolymer system23 and therefore also should be used with
caution. Nevertheless, one study24 suggested that dynamic
mechanical analysis (DMA) could detect amorphous phase
domains as small as 10 nm and a method based on solid state
NMR relaxation may be even more sensitive25.2.2. Storage stability and phase separation kinetics
At normal storage temperatures and with a desirable drug loading
(420%), drug in most solid dispersions far exceeds its equilibrium
solubility in the polymer matrix, which is difﬁcult to experimen-
tally measure but can be estimated (see Section 2.3). However, the
dispersion can be stable kinetically if the phase separations are
frozen below the glass transition temperature. Here we consider
instability from the point of view of drug crystallization to
illustrate why the rate of phase separation is slow at normal
storage temperatures.
In a homogeneous drug–polymer solution, polymer chains are
random coils that interpenetrate each other and extend through the
whole system, while drug molecules are dispersed randomly
among the polymer segments. It has been estimated that any
continuous drug domain within the random coils is no larger than
2.5 nm26, so that for a drug to form stable crystal nuclei a certain
amount of polymer must diffuse away. The time for this diffusion
to occur can be calculated from the polymer diffusion coefﬁcient,
the lower limit of which can be calculated on the basis of the
following two assumptions (Fig. 3): (1) The medium through
which the polymer diffuses essentially consists of pure drug (in
reality, the medium contains other polymer chains and the
viscosity is much higher than that in a pure drug domain); (2)
The medium viscosity is close to that at the glass transition
temperature i.e. viscosity 1012 Pa.s (again the storage tempera-
ture is usually below the glass transition temperature and the
viscosity is much higher). With these assumptions and for a
polymer about 10 nm in size, the diffusion coefﬁcient of the
polymer (the Rouse model27) is given by
Dﬃ kT
6πηR
 10–26 m2=s ð1Þwhich a polymer chain is diffusing out of a drug domain.
Y. Huang, W.-G. Dai22and the time for the polymer to diffuse over a distance of its own
size (10 nm) is
τﬃR
2
D
 100 years ð2Þ
Therefore, it is the high viscosity of the solid dispersion at the
glass state that stabilizes the dispersion structure. However, at
higher temperatures the viscosity of the drug–polymer mixture is
much lower (e.g., felodipine at 100 1C has a viscosity of
approximately 102 Pa.s)28, and the time scale for polymer diffu-
sion can be as low as seconds. Thus, for systems at higher
temperature in the molten state, the diffusion of both drug and
polymer are fast and phase separation can occur quickly.
As water is a very effective plasticizer, the absorption of
moisture signiﬁcantly decreases the glass transition tempera-
ture of a solid dispersion and consequently enhances the
mobility of drug and polymer. For example29, after storage
in a relative humidity of 53%, the glass transition temperature
of poly(vinyl pyrrolidone) (PVP K-12) was reported to
decrease from 170 1C to about 23 1C. Therefore, polymers
that are resistant to the absorption of water, such as HPMCAS
where the Tg remains 470 1C even after storage in a relative
humidity of 75%, have become the ﬁrst choice for the
preparation of stable solid dispersions9.
2.3. The drug–polymer interaction parameter and phase
diagram
A drug–polymer phase diagram can be constructed using the Flory–
Huggins polymer solution theory9,14. Taking the volume of a drug
molecule as the unit lattice volume, the free energy change
associated with mixing a polymer and small molecule is given by27
ΔG
ΚT
¼ ϕ ln ϕþ ð1ϕÞ
m
lnð1ϕÞ þ χϕð1ϕÞ ð3Þ
where K is the Boltzmann constant, T is the absolute temperature,
ϕ is the volume fraction of drug in the solid dispersion (i.e., the
drug loading), m is the volume ratio between polymer and drug,
and χ is the Flory drug–polymer interaction parameter representing
the difference between the drug–polymer contact interaction
(Fig. 4, right) and the average self-contact interactions of drug–
drug and polymer–polymer (Fig. 4, left). For example, hydrogen-
bond formation between drug and polymer chains [e.g., in the
fenbufen/poly(vinylpyrrolidone) pair] may make it more energeti-
cally favorable for the drug and polymer to interact with each other
rather than with themselves, resulting a negative interaction
parameter.
The Flory drug–polymer interaction parameter χ is key to
understanding the structures of solid dispersions and, according toFigure 4 The Flory interaction parameter of drug molecules and
polymer segments χ represents the energy difference between the inter-
species (i.e., drug–polymer) contact interaction (right) and the average
self-contact interactions (drug–drug and polymer–polymer) (left).the Flory–Huggins theory, is dependent only on temperature:
χ ¼Aþ B
T
ð4Þ
here A and B are constants independent of the drug loading and
polymer molecular weight. It should also be noted that χ is
dependent on the choice of unit volume27. Since the volume of a
drug molecule is usually chosen as the unit lattice volume, care is
needed when comparing interaction parameters between one
polymer and different drugs.
As shown by Lin and Huang14, the χ–T relationship allows the
whole phase diagram for a drug–polymer solid dispersion to be
constructed including both the drug solubility temperature curve
and the amorphous phase separation curve. As illustrated in detail
by Lin and Huang14, the χ–T relationship is obtained (Fig. 5) by
ﬁtting experimental melting point depression data (Tmϕ) to the
following equation which is based on the Flory–Huggins theory
(Eq. (5))30–32.
ΔH0m
R
1
T0m
 1
Tm
 
¼ ln ϕþ 1 1
m
 
ð1ϕÞ þ χTm ð1ϕÞ2 ð5Þ
Here ΔHm0 is the enthalpy of melting of pure drug crystals, R is the
ideal gas constant, Tm
0 and Tm are the melting points of the pure
drug crystals and drug crystals in the solid dispersion with drug
volume faction of ϕ. Please note that the drug–polymer interaction
parameter χ is temperature dependent and the value in Eq. (5) is
that at the temperature Tm. When using Eq. (5), χ is usually
assumed to be constant and, because the experimentally available
Tm range is narrow, this assumption holds true and melting point
depression data can give a good ﬁt to Eq. (5). However, when
Eq. (5) is used to estimate drug solubility at low temperatures such
as at the storage temperature, the χ–T variation cannot be neglected
(Fig. 5)33 without overestimating drug solubility.
The accurate measurement of equilibrium melting points of
drug crystals in solid dispersions also represents a considerable
challenge. Currently, most researchers use the method developed
by Tao et al.32 where melting points are measured at different
heating rates and extrapolated to zero heating rate to estimate the
equilibrium value. In this method, the solid dispersion is prepared
by intimate mixing of drug crystals and polymer via cryogenicFigure 5 The predicted χ–T relationship (Eq. (4)) for the felodipine/
poly(acrylic acid) and fenbufen–poly(vinyl pyrrolidone) drug polymer
systems. The original melting point depression data used in the
calculation are taken from Refs. 14 and 33.
Solid dispersion technology for poorly soluble drugs 23milling. Alternatively, the sample may also be prepared by
conventional methods (melt extrusion, spray drying, and co-
precipitation) and then annealed at suitable temperature to generate
drug crystals in situ14. One advantage of the direct mixing method
is being able to avoid complications of drug crystal polymorphism.3. Drug–polymer interactions in dissolution
The ultimate success of a solid dispersion is determined by its
performance in dissolution after oral administration. The general
strategy behind almost all solubilization technologies is the so-
called “spring-and-parachute” concept34. For a solid dispersion,
this means that the drug should ﬁrst dissolve along with the
soluble polymer matrix to create a supersaturated solution (“the
spring”) after which supersaturation is maintained long enough for
drug absorption (“the parachute”) to take place.
Depending on the type of solid dispersion, dissolution can
occur in three possible ways (Fig. 6). When the drug loading is
low, the drug and polymer in the solid dispersion dissolve rapidly
(Fig. 6A) after which drug is continuously absorbed and can
undergo precipitation in the presence of polymer and endogenous
compounds such as bile acids, phospholipids and mucin.
As described in detailed by Friesen et al.9, various structures
may form including free drug (the major species, if not theFigure 6 Three possible scenarios of drug dispersion from solid dispe
supersaturated solution; subsequently drug precipitates as amorphous and
(B) drug and polymer are gradually released while drug remains amorphou
released but drug is present as crystals in the undissolved particles especial
solubility of either amorphous or crystalline drug which in turn depe
crystallization rate.only species, being absorbed, so its concentration is what matters
for absorption), drugs in bile salt/phospholipid micelles, amor-
phous drug nanoprecipitates with polymers, and possibly drug
nanocrystals stabilized with polymers, all of which are in dynamic
exchange with each other. Since such nanoparticles can escape
ﬁltration or centrifugation, the apparent solubility of a drug can be
erroneously high. Nevertheless, with the proper choice of poly-
mers, the free drug concentration can be maintained at the
solubility of amorphous drugs9,35. However, it should be noted
that, in theory, the highest concentration of free drug in the
dissolution media is even higher, corresponding to the spinodal
amorphous phase separation line, above which the drug forms
amorphous aggregates spontaneously36.
Solid dispersions generate a supersaturated drug solution when
exposed to the aqueous environment of the gastrointestinal tract.
Drugs in this state have a tendency to precipitate rapidly before
being absorbed resulting in reduced bioavailability. A variety of
polymer excipients have been evaluated for their ability to prolong
the supersaturation and inhibit drug precipitation37. Fortunately,
the polymers commonly used in the preparation of solid disper-
sions are generally the same ones that inhibit drug precipitation,
speciﬁcally some cellulose derivatives such as hydroxypropyl
methylcellulose (HPMC) and hydroxypropylmethylcellulose acet-
ate succinate (HPMCAS) and vinyl polymers such as poly
(vinylpyrrolidone) (PVP) and poly(vinylpyrrolidone-co-vinylrsions. (A) Particles dissolve rapidly and release drug into a highly
/or crystalline particles onto which polymer adsorbs as a stabilizer;
s in the undissolved particles; and (C) drug and polymer are gradually
ly near their surfaces. The free drug concentration is dependent on the
nds on the drug/polymer ratio, polymer dissolution rate and drug
Y. Huang, W.-G. Dai24acetate) (PVPVA). These polymers are able to maintain a super-
saturated drug concentration in vivo for an extended period of time
to allow optimal absorption.
The mechanism of how polymers prolong drug supersaturation
is still not fully understood despite considerable research but is
generally believed to result from a polymer–drug interaction. Drug
precipitation (or crystallization) takes place in two stages viz.
nucleation and crystal growth. The polymers in solid dispersions
may interfere with one or both of these processes by interacting
with the drug or changing the properties of the medium38,39. Thus
some polymers are known to suppress the nucleation process40
while others adsorb on the surface of crystals to block the access
of solute molecules (“the poisoning effect”) thus preventing or
retarding crystal growth41,42.
The polymer–drug interactions may mainly be the result of
hydrogen bond formation and/or hydrophobic interactions. For
example, studies have shown that HPMC is effective in inhibiting
nucleation of drugs rich in hydrogen-bond acceptors43–45 in a
concentration dependent manner40. This ability to delay nucleation
may be because hydrogen bonds between drug molecules and
polymers not only increase the nucleation activation energy but
also reduce crystal growth46–48.
Hydrogen bonding is not the only type of interaction that
inﬂuences drug precipitation/dissolution in solid dispersions.
Studies have also shown that the higher the lipophilicity of a
polymer the more it is able to inhibit/retard nucleation and/or
crystal growth49–51. This is because a polymer with a higher
lipophilicity adsorbs more effectively onto crystal surfaces to
enhance the inhibition of further drug attachment52,53. However,
there is an upper limit to polymer lipophilicity above which the
inhibition effect is lost54. In addition, other factors such as steric
hindrance to adsorption, polymer rigidity and distribution of
functional groups in the polymer may play a signiﬁcant role in
the polymer–drug interaction. For example, polymers with rela-
tively rigid structures can adsorb onto crystal surfaces more easily
to inhibit drug precipitation54,55.
In the scenario described above, the dissolution of the solid
dispersion is fast and complete and the supersaturated solution around
the solid dispersion determines the concentration of free drug. In
contrast, solid dispersion particles may dissolve slowly either because
of high drug loading or the nature of the polymer resulting in a more
sustained release proﬁle. As water continuously penetrates into solid
dispersion particles, phase separation eventually occurs. If drug
crystallization is still inhibited by the polymer matrix in this situation,
the drug may form amorphous aggregates (Fig. 6B) and the free drug
concentration in the dissolution media will be equal to the solubility
of amorphous drugs. However, if the drug is present in a crystalline
state in the solid dispersion particles (Fig. 6C), the free drug
concentration in the solution decreases to that of the solubility of
drug crystals, i.e., the dissolution advantage of the solid dispersion is
lost35,56,57.4. Summary
As an increasing proportion of drugs undergoing development are
poorly water-soluble, solubilization technologies have become an
essential feature in bringing them successfully to market. The solid
dispersion is one such technology which in recent years has led to
the approval of a large number of products, suggesting it is now
the preferred technology for drug solubilization. However, despite
considerable progress in understanding the nature of soliddispersions, many aspects of their behavior remain to be clariﬁed
such as the kinetics of phase separation in the solid state and in
solution, and even such simple questions as how polymer
molecular weight affects the drug crystallization rate. Research
is also needed into the use of solid dispersions in conjunction with
controlled release technologies such as the osmotic pump.Acknowledgment
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